Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

Author Guidelines

Manuscript Requirements:

1. The length of the manuscript is not more than 20 pages.

2. The title of the manuscript is not more than 15 words and must reflect the contents of the manuscript, followed by the name of the author and the author's institution.

3. Abstract of no more than 200 words.

4. Brief Introduction explains the background of the research problem and research objectives.

5. Materials and methods are clearly explained. New techniques and modified methods need to be described in more detail. The standard method only includes references.

6. Results and Discussion are described briefly and clearly. Results are presented using Tables or Figures and are not repeated in the text. The table is made one spaced with the same letter as the text, no vertical lines, super clip, 3 illustrations/pictures sent, one of which must be sharp enough to be original to be reproduced.

7. Conclusions are briefly summarized by considering the title of the manuscript, the aims and objectives, and the results of the research.

8. Acknowledgments if any and written no more than 40 words.

9. References must be mentioned in the text with the author's surname or last name and year of publication, written Lubis, M.A. (2018) or (Lubis, M.A., 2018). For references of more than four authors, the first author is mentioned first followed by et al. for foreign writers. Bibliography is arranged alphabetically without serial number: author's name, year of publication, article title, book title, name and journal number, publisher and city of publication, and page number. If any, the DOI of the article should be written as follows:

Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ 2020; 370: 3026.

Jakarta Health Office. Jakarta Health Profile 2017: Jakarta Health-Office; 2018. Cited on 2 July 2018.

Kidney International Supplements. Kidney disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for acute kidney injury. Published March 2012. Accessed July 11, 2019.

Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulmonary Medicine.

Ren B, et al. Procalcitonin and Survival Study (PASS) Group. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;2:e000635.

Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. J Hosp Med. 2017;12(2):77–82. doi:10.12788/jhm.2684.

Si Z-L, Kang L-L, Shen X-B, Zhou Y-Z. Adjuvant efficacy of nutrition support during pulmonary Tuberculosis treating course: Systematic review and meta-analysis. Chinese Med J. 2015;128.

World Health Organization. Global Tuberculosis Report 2018. France: WHO; 2018.

Zhang C, Wu Z, Li JW, Tan K, Yang W, Zhao H, et al. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021; 93: 1378-86.

10. Unpublished references can be used as references, but must be included in the text (eg Suparno, unpublished).

11. Unusual acronyms or abbreviations are written in full on the skin first and then written only abbreviations. Unusual abbreviations should be avoided unless they appear frequently in the text.

12. Latin names, families, and species are written first together with their common names. Next, the name is generally written. 

13. The International System of Units should be used for all units.

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.